¼¼°èÀÇ ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH) ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® - À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), By End Use (Pharma & CRO Industry, Hospitals), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1726370
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,242,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,627,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,398,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 56¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ¿¹Ãø ±â°£ µ¿¾È CAGR 23.3%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºñ¸¸ ¹× ´ç´¢º´ µîÀÇ ¿äÀο¡ ÀÇÇÑ ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH) À¯º´·üÀÇ »ó½ÂÀÌ NASH ¹ÙÀÌ¿À¸¶Ä¿ ¼ö¿ä¸¦ Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH)ÀÇ Áø´Ü °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀº Á¤È®ÇÑ Áø´Ü µµ±¸ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, °è¹ß, Á¶±â ¹ß°ß, ¿¬±¸ Á¶¼ºÀ» ÃËÁøÇÏ´Â Á¤ºÎ ¹× ÀÇ·áÀÇ ´ëó°¡ ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº NASHÀÇ ºÎ´ã Áõ°¡¸¦ ÇØ°áÇÏ°í ¹ÙÀÌ¿À¸¶Ä¿ °³¹ßÀ» ÅëÇØ Áúº´ °ü¸®¸¦ °³¼±ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

Áø´Ü ±â¼úÀÇ ¹ßÀü ¹× Á¶±â ¹ß°ß¿¡ ´ëÇÑ °ü½É Áõ°¡´Â NASH ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. À̹Ì¡ ±â¼ú ¹× Ç÷¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿¿Í °°Àº Çõ½ÅÀûÀÎ ºñħ½ÀÀû °Ë»ç ¹æ¹ýÀ» ÅëÇØ º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´ÜÀÌ °¡´ÉÇÕ´Ï´Ù. Á¶±â ¹ß°ßÀ¸·Î Ä¡·á ¼ºÀûÀÌ Çâ»óµÊ¿¡ µû¶ó Áúº´ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϱâ À§ÇÑ Ã·´Ü ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯¹Ç·Î Á¶±â °³ÀÔÀ» Áß½ÃÇÏ´Â ÀÇ·á Á¦µµ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí NASH °ü¸®¸¦ À§ÇÑ °³¼± µÈ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

NASH¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡´Â È¿°úÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀåÀÇ ´ëÆøÀûÀÎ ¼ºÀåÀ¸·Î À̾îÁú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áúȯ¿¡ ´ëÇÑ ÀνÄÀÇ °íÁ¶´Â Á¶±â Áø´Ü°ú ´õ ³ªÀº Áúȯ °ü¸®¸¦ ÃËÁøÇÕ´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­ÀÇ ¿¬±¸°³¹ß È®´ë´Â ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ßÀ» ÃËÁøÇϰí Áø´Ü Á¤È®µµ¿Í Ä¡·á Àü·«À» Çâ»ó½Ãŵ´Ï´Ù. ÀÌµé ¿äÀÎÀÌ NASH ¹ÙÀÌ¿À¸¶Ä¿ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ½ÃÀå È®´ë¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : º¯µ¿ ¿äÀÎ, °æÇâ ¹× ¹üÀ§

Á¦4Àå ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : À¯Çüº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The global non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 5.68 billion by 2030 and expand at a CAGR of 23.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of Non-alcoholic Steatohepatitis (NASH), fueled by factors such as obesity and diabetes, is significantly driving the demand for NASH biomarkers. The growing diagnosis of NASH drives the demand for accurate diagnostic tools. In addition, government and healthcare initiatives promoting awareness, early detection, and research funding further accelerate market growth. These efforts are crucial in addressing the growing burden of NASH and improving disease management through biomarker development.

Advancements in diagnostic technologies and an increased focus on early detection drive the growth of the NASH biomarkers market. Innovative noninvasive testing methods such as imaging techniques and blood-based biomarkers enable quicker, more accurate diagnoses. Early detection improves treatment outcomes, fueling demand for advanced biomarkers to monitor disease progression. Hence, the growing emphasis of healthcare systems on early intervention impels market growth, helping provide improved solutions for NASH management.

Growing awareness of NASH is expected to propel the demand for effective biomarkers, leading to significant market growth. Increasing recognition of the disease encourages earlier diagnosis and better disease management. Expanding research and development in the field advances the discovery of novel biomarkers, improving diagnostic precision and treatment strategies. These factors are anticipated to drive the demand for NASH biomarkers, contributing to the market expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends, & Scope

Chapter 4. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

Chapter 5. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Estimates & Trend Analysis

Chapter 6. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â